BACKGROUND: Combined treatment with an angiotensin-converting enzyme inhibitor and a mineralocorticoid receptor (MR) antagonist improved cardiac and skeletal muscle function and pathology in a mouse model of Duchenne muscular dystrophy. MR is present in limb and respiratory skeletal muscles and functions as a steroid hormone receptor. OBJECTIVE: The goals of the current study were to compare the efficacy of the specific MR antagonist eplerenone with the non-specific MR antagonist spironolactone, both in combination with the angiotensin-converting enzyme inhibitor lisinopril. METHODS: Three groups of n=18 dystrophin-deficient, utrophin-haploinsufficient male mice were given chow containing: lisinopril plus spironolactone, lisinopril plus eplerenone, or no drug, from four to 20 weeks-of-age. Eighteen C57BL/10 male mice were used as wild-type controls. In vivo measurements included cardiac magnetic resonance imaging, conscious electrocardiography, and grip strength. From each mouse in the study, diaphragm, extensor digitorum longus, and cardiac papillary muscle force was measured ex vivo, followed by histological quantification of muscle damage in heart, diaphragm, quadriceps, and abdominal muscles. MR protein levels were also verified in treated muscles. RESULTS: Treatment with specific and non-specific MR antagonists did not result in any adverse effects to dystrophic skeletal muscles or heart. Both treatments resulted in similar functional and pathological improvements across a wide array of parameters. MR protein levels were not reduced by treatment. CONCLUSIONS: These data suggest that spironolactone and eplerenone show similar effects in dystrophic mice and support the clinical development of MR antagonists for treating skeletal muscles in Duchenne muscular dystrophy.
BACKGROUND: Combined treatment with an angiotensin-converting enzyme inhibitor and a mineralocorticoid receptor (MR) antagonist improved cardiac and skeletal muscle function and pathology in a mouse model of Duchenne muscular dystrophy. MR is present in limb and respiratory skeletal muscles and functions as a steroid hormone receptor. OBJECTIVE: The goals of the current study were to compare the efficacy of the specific MR antagonist eplerenone with the non-specific MR antagonist spironolactone, both in combination with the angiotensin-converting enzyme inhibitor lisinopril. METHODS: Three groups of n=18 dystrophin-deficient, utrophin-haploinsufficient male mice were given chow containing: lisinopril plus spironolactone, lisinopril plus eplerenone, or no drug, from four to 20 weeks-of-age. Eighteen C57BL/10 male mice were used as wild-type controls. In vivo measurements included cardiac magnetic resonance imaging, conscious electrocardiography, and grip strength. From each mouse in the study, diaphragm, extensor digitorum longus, and cardiac papillary muscle force was measured ex vivo, followed by histological quantification of muscle damage in heart, diaphragm, quadriceps, and abdominal muscles. MR protein levels were also verified in treated muscles. RESULTS: Treatment with specific and non-specific MR antagonists did not result in any adverse effects to dystrophic skeletal muscles or heart. Both treatments resulted in similar functional and pathological improvements across a wide array of parameters. MR protein levels were not reduced by treatment. CONCLUSIONS: These data suggest that spironolactone and eplerenone show similar effects in dystrophicmice and support the clinical development of MR antagonists for treating skeletal muscles in Duchenne muscular dystrophy.
Authors: Luminita H Pojoga; Zuzana Adamová; Abhinav Kumar; Amanda K Stennett; Jose R Romero; Gail K Adler; Gordon H Williams; Raouf A Khalil Journal: Am J Physiol Heart Circ Physiol Date: 2010-04-02 Impact factor: 4.733
Authors: A E Deconinck; J A Rafael; J A Skinner; S C Brown; A C Potter; L Metzinger; D J Watt; J G Dickson; J M Tinsley; K E Davies Journal: Cell Date: 1997-08-22 Impact factor: 41.582
Authors: Christine Guo; Vincent Ricchiuti; Bill Q Lian; Tham M Yao; Patricia Coutinho; José R Romero; Jianmin Li; Gordon H Williams; Gail K Adler Journal: Circulation Date: 2008-04-21 Impact factor: 29.690
Authors: Wenning Qin; Amy E Rudolph; Brian R Bond; Ricardo Rocha; Eric A G Blomme; Joseph J Goellner; John W Funder; Ellen G McMahon Journal: Circ Res Date: 2003-06-05 Impact factor: 17.367
Authors: Simon Guiraud; Annemieke Aartsma-Rus; Natassia M Vieira; Kay E Davies; Gert-Jan B van Ommen; Louis M Kunkel Journal: Annu Rev Genomics Hum Genet Date: 2015-06-04 Impact factor: 8.929
Authors: Paul M L Janssen; Jason D Murray; Kevin E Schill; Neha Rastogi; Eric J Schultz; Tam Tran; Subha V Raman; Jill A Rafael-Fortney Journal: PLoS One Date: 2014-02-13 Impact factor: 3.240
Authors: J Spencer Hauck; Jeovanna Lowe; Neha Rastogi; Kevin E McElhanon; Jennifer M Petrosino; Kyra K Peczkowski; Ashlee N Chadwick; Jonathan G Zins; Federica Accornero; Paul M L Janssen; Noah L Weisleder; Jill A Rafael-Fortney Journal: Hum Mol Genet Date: 2019-06-15 Impact factor: 6.150
Authors: J Spencer Hauck; Zachary M Howard; Jeovanna Lowe; Neha Rastogi; Madison G Pico; Sarah A Swager; Jennifer M Petrosino; Celso E Gomez-Sanchez; Elise P Gomez-Sanchez; Federica Accornero; Jill A Rafael-Fortney Journal: Front Physiol Date: 2019-10-25 Impact factor: 4.566
Authors: Kyra K Peczkowski; Neha Rastogi; Jeovanna Lowe; Kyle T Floyd; Eric J Schultz; Tallib Karaze; Jonathan P Davis; Jill A Rafael-Fortney; Paul M L Janssen Journal: Front Physiol Date: 2020-09-25 Impact factor: 4.566
Authors: Andrea Vecchiola; Cristóbal A Fuentes; Isidora Solar; Carlos F Lagos; Maria Cecilia Opazo; Natalia Muñoz-Durango; Claudia A Riedel; Gareth I Owen; Alexis M Kalergis; Carlos E Fardella Journal: Front Endocrinol (Lausanne) Date: 2020-04-21 Impact factor: 5.555